Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.

Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z, Hu Y, Wu C, Nardone J, MacNeill J, Ren J, Reeves C, Innocenti G, Norris B, Yuan J, Yu J, Haack H, Shen B, Peng C, Li H, Zhou X, Liu X, Rush J, Comb MJ.

PLoS One. 2011 Jan 6;6(1):e15640. doi: 10.1371/journal.pone.0015640.

2.

ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma.

Liu P, Wu Y, Sun L, Zuo Q, Shi M.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr;33(4):474-8.

PMID:
23644102
3.

Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells.

Deng G, Hu C, Zhu L, Huang F, Huang W, Xu H, Nie W.

Int J Mol Med. 2014 Sep;34(3):661-8. doi: 10.3892/ijmm.2014.1823. Epub 2014 Jun 27.

4.

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.

Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T, Shibata T.

Hepatology. 2014 Apr;59(4):1427-34. doi: 10.1002/hep.26890. Epub 2014 Feb 18.

PMID:
24122810
5.

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.

Cancer Res. 2006 Aug 1;66(15):7473-81.

6.

[Activated serine/threonine kinase AKT enhances the radioresistancy in human cholangiocarcinoma].

Yanagawa N.

Hokkaido Igaku Zasshi. 2003 Mar;78(2):159-71. Japanese. No abstract available.

PMID:
12704859
7.

The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.

Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A.

Cancer Res. 2012 Aug 1;72(15):3764-74. doi: 10.1158/0008-5472.CAN-11-3990. Epub 2012 Jun 1.

8.

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S.

Mol Cancer Ther. 2006 Jul;5(7):1895-903.

9.

Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.

Nakajima Y, Takagi H, Kakizaki S, Horiguchi N, Sato K, Sunaga N, Mori M.

Anticancer Res. 2012 Dec;32(12):5251-62.

PMID:
23225424
10.

Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.

Shen DY, Zhan YH, Wang QM, Rui G, Zhang ZM.

Liver Int. 2013 Jan;33(1):137-48. doi: 10.1111/liv.12014. Epub 2012 Nov 1.

PMID:
23121546
11.

The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells.

Dai R, Li J, Fu J, Chen Y, Wang R, Zhao X, Luo T, Zhu J, Ren Y, Cao J, Qian Y, Li N, Wang H.

J Biol Chem. 2012 Nov 16;287(47):39812-23. doi: 10.1074/jbc.M112.406520. Epub 2012 Sep 28.

12.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ.

Cell. 2007 Dec 14;131(6):1190-203.

13.

Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1.

Keilhack H, Müller M, Böhmer SA, Frank C, Weidner KM, Birchmeier W, Ligensa T, Berndt A, Kosmehl H, Günther B, Müller T, Birchmeier C, Böhmer FD.

J Cell Biol. 2001 Jan 22;152(2):325-34.

14.

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19513-8. doi: 10.1073/pnas.1311707110. Epub 2013 Oct 23.

15.
16.

Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma.

Tanaka S, Sugimachi K, Kameyama T, Maehara S, Shirabe K, Shimada M, Wands JR, Maehara Y.

Hepatology. 2003 May;37(5):1122-9.

PMID:
12717393
17.

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H.

Clin Cancer Res. 2012 Aug 15;18(16):4449-57. doi: 10.1158/1078-0432.CCR-11-3351. Epub 2012 Jun 1.

20.

Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.

Sirica AE, Lai GH, Endo K, Zhang Z, Yoon BI.

Semin Liver Dis. 2002 Aug;22(3):303-13.

PMID:
12360423

Supplemental Content

Support Center